New Zealand markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
84.50+3.11 (+3.82%)
At close: 04:00PM EST
84.54 +0.04 (+0.05%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close81.39
Open84.65
Bid84.01 x 900
Ask84.46 x 1800
Day's range83.62 - 86.97
52-week range57.17 - 89.74
Volume12,852,404
Avg. volume7,390,108
Market cap105.983B
Beta (5Y monthly)0.43
PE ratio (TTM)32.01
EPS (TTM)2.64
Earnings date26 Apr 2023 - 01 May 2023
Forward dividend & yield2.92 (3.48%)
Ex-dividend date14 Dec 2022
1y target est87.54
  • Zacks

    Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

    Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

  • Business Wire

    U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

    FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in

  • Motley Fool

    Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?

    Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015." Is Gilead Sciences stock a buy after its strongest results in seven years?